{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:53:46Z","timestamp":1788893626976,"version":"build-2803163510"},"reference-count":6,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.ejca.2017.11.008","type":"journal-article","created":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T00:14:20Z","timestamp":1512951260000},"page":"146-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Metastatic cutaneous apocrine adenocarcinoma responsive to the programmed cell death protein 1\u00a0inhibitor pembrolizumab"],"prefix":"10.1016","volume":"90","author":[{"given":"Max","family":"Rogatsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigurd","family":"Lax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Uranitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Schmid-Zalaudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Giuffrida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Zalaudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2017.11.008_bib1","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.11.008_bib2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/jso.22023","article-title":"Cutaneous apocrine adenocarcinoma: defining epidemiology, outcomes, and optimal therapy for a rare neoplasm","volume":"105","author":"Hollowell","year":"2012","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejca.2017.11.008_bib3","doi-asserted-by":"crossref","DOI":"10.1186\/s12957-015-0473-1","article-title":"Primary apocrine sweat gland carcinomas of the axilla: a report of two cases and a review of the literature","volume":"13","author":"Seong","year":"2015","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.ejca.2017.11.008_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1001\/jamadermatol.2015.2507","article-title":"Metastatic cutaneous apocrine adenocarcinoma treated with a combination of pertuzumab-based targeted therapy and taxane chemotherapy: a case report","volume":"152","author":"Otsuka","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2017.11.008_bib5","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti\u2013pd-l1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.11.008_bib6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2017.06.022","article-title":"Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: case report and review of the literature","volume":"83","author":"Deinlein","year":"2017","journal-title":"Eur J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917314053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917314053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T16:27:37Z","timestamp":1573489657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917314053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":6,"alternative-id":["S0959804917314053"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.11.008","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metastatic cutaneous apocrine adenocarcinoma responsive to the programmed cell death protein 1\u00a0inhibitor pembrolizumab","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}